Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer.
Saved in:
| Title: | Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer. |
|---|---|
| Authors: | Apolo A; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Baumann BC; Department of Radiation Oncology, Springfield Clinic, Springfield, IL, USA.; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA., Al-Ahmadie H; Department of Pathology and Laboratory Medicine, Genitourinary Pathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ballas L; Department of Radiation Oncology, Cedars Sinai Medical Center, Los Angeles, CA, USA., Bangs R; Patient Advocate, Bladder Cancer Advocacy Network, Bethesda, MD, USA., Brothers K; Patient Advocate, National Cancer Institute Bladder Cancer Task Force, Rockville, MD, USA., Greenberg SC; Patient Advocate, National Cancer Institute Bladder Cancer Task Force, Rockville, MD, USA.; Patient Advocate, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA., Delacroix S; Department of Urology, Louisiana State University Health Science Center, New Orleans, New Orleans, LA, USA., Dignam JJ; Department of Public Health Sciences, University of Chicago, Chicago, IL, USA., Efstathiou JA; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Feldman AS; Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Foster JC; Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD, USA., Hahn NM; Departments of Oncology and Urology, Johns Hopkins University, Greenberg Bladder Cancer Institute, Baltimore, MD, USA., Hall E; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., Hansel DE; Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hoffman-Censits J; Departments of Oncology and Urology, Johns Hopkins University, Greenberg Bladder Cancer Institute, Baltimore, MD, USA., Kamat AM; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kamran SC; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Khani F; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA., Lerner SP; Scott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA., Lipman R; Patient Advocate, Bladder Cancer Advocacy Network, Bethesda, MD, USA., Mann B; Cancer Therapy Evaluation Program, National Cancer Institute, NIH, Rockville, MD, USA., McConkey D; Departments of Oncology and Urology, Johns Hopkins University, Greenberg Bladder Cancer Institute, Baltimore, MD, USA., McKiernan J; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA, Department of Urology, Columbia University, New York, NY, USA., Rose TL; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Smith AB; Department of Urology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Tangen C; SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Amiri AT; Coordinating Center for Clinical Trials, National Cancer Institute, NIH, Bethesda, MD, USA., Weinstock C; Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, MD, USA., West PJ; Emmes Company, Rockville, MD, USA., Milowsky MI; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Black PC; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. |
| Source: | Bladder cancer (Amsterdam, Netherlands) [Bladder Cancer] 2025 Feb 24; Vol. 11 (1), pp. 23523735251319185. Date of Electronic Publication: 2025 Feb 24 (Print Publication: 2025). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: IOS Press Country of Publication: United States NLM ID: 101668567 Publication Model: eCollection Cited Medium: Internet ISSN: 2352-3735 (Electronic) Linking ISSN: 23523727 NLM ISO Abbreviation: Bladder Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
